Summary We have studied the relationship between expression of genes implicated in mediating resistance to cleavable complex-forming topoisomerase 11 (topo 11) inhibitors and cellular sensitivity to ICRF-159, a 'catalytic' inhibitor of topo 11. Overexpression of the membrane transporters, P-glycoprotein and multidrug resistance-related protein (MRP), or down-regulation of topo lla and/or -1, did not confer ICRF-159 resistance. Indeed, marked topo Ila down-regulation appeared to be associated with collateral sensitivity to ICRF-159. Our results indicate that the resistance mechanisms that pertain to cleavable complex-forming topo 11 inhibitors and ICRF-159 are distinct. The evidence presented here suggests that topo lla, not topo llp, is more likely to be the major in vivo target for ICRF-159.
Topo II has been identified as the primary cellular target for many of the most effective and widely used anti-cancer drugs, including etoposide, mitoxantrone, epirubicin and doxorubicin (reviewed in Pommier, 1993; Froelich-Ammon and Osheroff, 1995) . However, the development of drug resistance limits the clinical efficacy of these topo II-targeting agents. The best characterized mechanism of resistance to topo II-targeting drugs is a change in drug accumulation mediated by alterations in the expression of the multidrug resistance protein, P-glycoprotein (Bradley and Ling, 1994 ) and the multidrug resistance-related protein, MRP (Cole et al, 1992) . However, alterations other than those involving membrane-associated drug transport proteins can give rise to a multidrug-resistant (MDR) phenotype. One such form of MDR, which has been termed atypical MDR, is associated with alterations in the expression or activity of topo II (reviewed in Beck et al, 1993; Pommier, 1993) .
Depending upon their mechanism of action, topo II-targeting drugs fall into two distinct classes. The members of one class exert their cytotoxic effect via the stabilization of a normally transient reaction intermediate, termed the cleavable complex, which is formed when the enzyme becomes covalently bound to the 5' ends of the cut duplex DNA (Liu et al, 1983) . Most of the topo IItargeting drugs currently in clinical use operate via this general mechanism. Elevated levels of topo II confer increased sensitivity to this class of drugs (Davies et al, 1988) , while the acquisition of drug resistance is usually associated with a reduction in nuclear topo II levels (reviewed in Beck et al, 1993; Pommier, 1993) . A second class of topo II inhibitors exert their cytotoxic effects without the formation of cleavable complexes. These inhibitors include the thiobarbiturate derivative, merbarone, and the bis-2,6-dioxopiperazine derivatives, MST-16, ICRF-193 and ICRF-159 (Tanabe et al, 1991; Chen and Beck, 1995) . These non-cleavable complex-forming compounds act via the prevention of the reversible opening and Correspondence to: ID Hickson closing of the topo II 'clamp', which captures DNA during the catalysis of DNA topology changes (Roca et al, 1994) . This class of 'catalytic' inhibitors might be expected to be more toxic to MDR cell lines expressing reduced levels of topo II, although experimental evidence supporting this notion has not yet been presented. Here, we have studied whether the same cellular resistance mechanisms operate in response to the two classes of topo II-targeting agents -those that form cleavable complexes and those that act independently of the formation of DNA strand breaks.
MATERIALS AND METHODS Human cell lines
The testicular teratoma cell line SuSa, the breast cancer cell line MCF-7, the sarcoma cell line MES-SA, the leukaemic cell line CEM and the two small-cell lung cancer cell lines, NCI-460 and U 1285, together with their corresponding resistant sublines, SuSa-VPC2, MCF-7-AdrR, CEM/MX1, MES-SA clone 1-4G1 1 and MES-SA clone 05-lF1, NCI-460/pV8 and U-1285-dox800, were used in this study. All cell lines were maintained in RPMI-1640 medium, supplemented with fetal bovine serum (10%) and the antibiotics penicillin (100 U ml-') and streptomycin (100 ,ug ml-'). Cells were grown at 37°C in a humidified atmosphere containing 5% carbon dioxide. All cell lines were routinely tested for Mycoplasma by fluorescence microscopy of Hoecht 33258-stained cells and were found to be negative.
Clonogenic assays
ICRF-159 was dissolved in dimethyl sulphoxide (DMSO) and stored in aliquots at -20°C. Adherent cells were seeded at 1000 cells per 9-cm Petri dish, allowed to adhere for 4 h and were then exposed to different concentrations of ICRF-159 for 24 h. An equivalent volume of DMSO to that used in the highest drug dose was added to the drug-free control plates. Cells were incubated for 14 days to allow colony formation. Colony fixation and staining were carried out as described previously (Davies et al, 1988 ).
Growth inhibition assays
The effect of ICRF-159 on the growth of the non-adherent cell lines, U-1285 and CEM, and their corresponding resistant sublines, U-1285-dox800 and CEMIMX1, was assessed by growing 2 x 105 cells ml-' in various concentrations of drug over a 7-day period and determining cell numbers at timed intervals using a Neubauer haemocytometer.
Preparation of mRNA
Total cellular RNA was prepared according to the method of Chomczynski and Sacchi (1987) . RNA concentration was determined spectophotometrically, and the integrity of the mRNA was assessed by agarose gel electrophoresis and ethidium bromide staining.
Ribonuclease protection assays
This procedure was carried out essentially as described by Ausubel et al (1987) . The topo Ila and -P probes used were generated as described by Jenkins et al (1992) . These probes produced protected fragments of 215 bp for topo Ila and two fragments of 228 and 296 bp corresponding to the differentially spliced topo Hlp-I and topo II-2 mRNAs (Davies et al, 1993) . The MRP probe (Cole et al, 1992 ) gave rise to a protected fragment of 270 bp. mRNA expression levels were determined by densitometric analysis of autoradiographs using a Bio-Image analyser (Milligen/BioSearch). mRNA levels were equalized in terms of the level of mRNA for an internal loading control -in this case the housekeeping gene, glyceryldehyde-3-phosphate dehydrogenase (GADPH), which produced a protected fragment of 120 bp.
Western blot analysis
Crude nuclear extracts were prepared as described by Glisson et al (1986) . Samples were equalized in terms of their total nuclear protein content and then visualized by Coomassie blue staining of 7.5% sodium dodecyl sulphate (SDS) polyacrylamide gels (Laemmli, 1970) . Samples were transferred from the gel to nitrocellulose; the filters were blocked with 2% low-fat milk and then incubated with either a mouse monoclonal antibody to topoisomerase 11a (Cambridge Research Biochemicals) or a rabbit polyclonal antibody to topoisomerase II3 (Houlbrook et al, 1995) .
RESULTS AND DISCUSSION Drug resistance characteristics of the cell lines
The drug-resistant cell lines used in this study display the range of genetic and/or epigenetic changes most commonly associated with resistance to topo II inhibitors. SuSa-VPC2 cells represent a resistant derivative of a testicular teratoma cell line (Hoskins et al, 1994) , a cell type that demonstrates exquisite sensitivity to multiple drugs, both in vitro and in vivo. The MCF-7-AdrR breast cancer cell line has been shown previously to display marked overexpression of P-glycoprotein (Moscow et al, 1989) , as well as increased glutathione-S-transferase (GST) activity (Batist et al, 1986) . The CEM/MX1 cell line shows extreme resistance to mitoxantrone (Danks et al, 1993) . With the exception of the MES-SA cells, all of the resistant cell lines were derived by chronic exposure to a topo II inhibitor. Moreover, these cell lines were isolated by exposure to several different classes of topo II inhibitor (Table 1) .
Expression of the topo 11 and MRP genes in drugresistant cell lines
The level of topo Ilo and -P mRNA expression in all of the parental and resistant cell lines was determined using RNAase protection assays. The data in Figure IA and Table 1 show that the SuSa-VPC2 subline displayed a reduced level of mRNA for both topo IIa and topo IlI (fourfold and threefold respectively). The MCF-7-AdrR subline exhibited a fourfold down-regulation of topo Ila mRNA and an approximately tenfold down-regulation of the two topo IIP mRNA species. A slight downregulation in the expression of topo Ila mRNA was observed in the NCI-460 pV8 cell line, with no apparent downregulation of the mRNA for the (Jaffrezou et al, 1994) . Thus, the drug-resistant cell lines studied showed no consistent pattern of altered topo II gene expression, although down-regulation of the mRNA for one or the other (or both) topo II isoforms was a general feature of this cell line panel (Table 1) The differing patterns of mRNA expression in the resistant variants was reflected in levels of topo II protein expression, as determined by Western blotting of nuclear protein extracts (Figure 2 ; Table 1 ). A similar analysis using whole-cell extracts gave equivalent results (data not shown). However, the degree of protein downregulation in each resistant variant was generally less marked than was the degree of mRNA down-regulation. Indeed, only in the case of the MES-SA cell-resistant derivatives was the degree of topo II protein down-regulation greater than 2.5-fold (Table 1) .
Measurement of sensitivity to ICRF-159
In order to address whether the panel of drug-resistant cell lines showed an altered response to a non-cleavable complex-forming topo II-targeting agent, the parental and resistant variants were tested for their relative sensitivity to ICRF-159. The data in Figures 3 and 4 show that none of the resistant cell lines studied was cross-resistant to ICRF-159. Indeed, the MES-SA 05-FI 1 and 1-4G1 1 cell lines showed collateral sensitivity to ICRF-159. These British Journal of Cancer (1997) MES-SA-derived cell lines exhibit down-regulation of both topo II isoforms at the mRNA level (Jaffrezou et al, 1994 ), whereas at the protein level only the ox isoform appears to be significantly downregulated ( Figure 2 ; Table 1 ).
Relationship between topo 11 expression and sensitivity to topo Il-targeting drugs In agreement with many reports, our results show that a decrease in the level of the cellular target (topo II) is associated with relative resistance to cleavable complex-forming drugs (reviewed in Beck et al, 1993) . This is because the cytotoxicity of these agents is as a result of their ability to subvert topo II from its normal physiological role, in which DNA cleavage occurs only transiently, to one in which potentially cytotoxic double-stranded DNA breaks persist in the DNA. Conversely, down-regulation of the target enzyme might be expected to confer hypersensitivity to non-cleavable complex-forming topo 1I-targeting drugs, such as ICRF-159, which act as direct inhibitors of the catalytic activity of the enzyme. Such a relationship between a 'catalytic inhibitor' and its target enzyme is well established for drugs that target dihydrofolate reductase (reviewed in Fairchild et al, 1990 ) and thymidylate synthase (Freemantle et al, 1995) . Our study has shown that cell lines selected for resistance to cleavable complex-forming topo II inhibitors are not cross-resistant to ICRF-159. This is the case for a series of cell lines of different tissue origin, some of which exhibit a multidrug-resistant phenotype. This would indicate that overexpression of P-glycoprotein, MRP or certain classes of GSTs does not by itself confer resistance to ICRF-159.
Collateral sensitivity to ICRF-159 was seen only in the MES-SA 05-I Fl I and I -4G I I cell lines, despite the finding that some of the other representatives of this cell line panel showed a modest level of down-regulation of topo II protein. However, the MES-SA cell lines did show the greatest degree of topo IIoc protein downregulation. Despite this, there was no correlation between the extent of topo IIoc down-regulation and the degree of ICRF-159 sensitivity in the MES-SA cell lines. Thus, clone 05-IFI1 displayed a lower level of topo IIo protein than did clone 1-4GI 1, but both cell lines had similar ICRF-159 sensitivity. Nevertheless our results are consistent with the notion that the likely target for ICRF-159 is the topo IIoc protein in human cells and that down-regulation of the ix isozyme alone can confer sensitivity to ICRF-159, as the dramatic down-regulation of the f isoform in the CEM/MXI subline did not appear to influence the degree of ICRF-159 sensitivity. Clearly, further work will be required to confirm this suggestion. If this proves to be correct, our results suggest that sensitivity to ICRF-159 may only occur when the nuclear content of topo IIoc falls below a critical threshold level as members of the cell line panel other than 05-lFII and 1-4G11 exhibited a small down-regulation of topo Ila. The level that is set for this threshold might be dependent upon the requirement in each cell line for a particular level of topo IIoc activity during chromosome segregation at mitosis.
Cells of testicular germ cell origin are very sensitive, in vivo and in vitro, to a wide range of drugs, including cis-platinum and bleomycin. However, the testicular teratoma cell line, SuSa, was more resistant to ICRF-159 than any of the other parental cell lines studied. The high basal topo II activity in the parental SuSa cell line (Fry et al, 1991) might be responsible for the intrinsic resistance of this line to ICRF-159 compared with other epithelial cell lines.
In the clinical situation, where resistance to cleavable complexforming topo IL-targeting drugs is encountered all too frequently (although whether this is conferred by changes in topo II is not known), it would be interesting to analyse whether patients still respond to treatment with topo II-targeting drugs, such as ICRF-159, which act via a distinct mechanism. Bis(2,6-dioxopiperazine) derivatives have previously been shown to have some anti-tumour activity in leukaemia and sarcomas. Marrow suppression was the dose-limiting toxicity in Phase II studies, and use of the drug was generally discontinued (Tsukagoshi, 1994) . Re-evaluation of this drug (or an analogous agent) may be indicated, in combination with marrow support provided by colony-stimulating factors.
